Company profile
XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases in Israel. The company's lead drug candidate is hCDR1, which is a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. It has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications. The
- CEO
- Mr. Noam Band
- Headquarters
- Herzliya, Israel
- Employees
- 4
- IPO date
- Sep 1, 2005
- Sector
- Healthcare
- Industry
- Biotechnology